Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetic/PK data for inhaled mosliciguat in healthy male volunteers. The peer-reviewed manuscript, titled “Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men,” was published in the journal Clinical Pharmacokinetics.

The findings support the potential for once-daily inhaled administration of mosliciguat as a treatment option for patients with pulmonary hypertension/PH, suggesting a longer half-life compared to oral and IV administration, which could lead to limited systemic side effects. The published manuscript details three Phase 1 studies that characterized the PK profile of mosliciguat following inhalation via a low-resistance device using a lactose carrier-based dry powder formulation.

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

A research scientist in a lab coat examining a sample of blood for sickle cell diseases.

In all three studies, mosliciguat was well tolerated, with no major systemic effects observed on heart rate or blood pressure. The data indicate a long residence time for the drug in the lungs and a slow, continuous release into the systemic circulation. PH is a progressive and debilitating condition characterized by high blood pressure in the lungs’ blood vessels, which leads to symptoms like shortness of breath and fatigue.

Pulmovant is a clinical-stage biotechnology company and a Roivant company. Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines and technologies.

While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.